Ones To Watch News
Refine Search
Biotechnology
Tuesday is shaping up to be another dark day in the stock market for US genetic medicines company Sarepta Therapeutics as key trial data were announced. 4 November 2025
Pharmaceutical
Pfizer today announced that it has filed a second lawsuit against Metsera, its controlling stockholders, and Novo Nordisk in the US District Court for the District of Delaware. 3 November 2025
Biotechnology
US clinical-stage CRISPR genome-editing company Caribou Biosciences today announced positive results from its ongoing ANTLER Phase I clinical trial evaluating vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). 3 November 2025
Biotechnology
Germany-based Immatics has this month announced updated clinical data from its PRAME-directed TCR T-cell therapy, anzu-cel (anzutresgene autoleucel, IMA203), in 16 patients with metastatic uveal melanoma. 3 November 2025
Biotechnology
UK-based neuropsychiatry company Draig Therapeutics has announced the appointment of Ivana Magovčević-Liebisch as president and chief executive. 3 November 2025
Pharmaceutical
UK-based specialty CNS-focused pharma company CNX Therapeutics says it has acquired the global Sativex (nabiximols) business from USA-based Jazz Pharmaceuticals. 3 November 2025
Pharmaceutical
US pharma giant Pfizer revealed on Friday that it has filed a lawsuit against Metsera, its board of directors, and Denmark’s Novo Nordisk in the Delaware Court of Chancery. 1 November 2025
Biotechnology
Germany-based biotech Tubulis today announced a second and final closing of its Series C round totaling 344 million euros ($401million). 30 October 2025
Pharmaceutical
Austrian biotech VALANX Biotech has appointed Klaus Orlinger as chief scientific officer, reinforcing its leadership as the company advances its first antibody-drug conjugate (ADC), VLX-ADC-001, toward candidate selection. The move signals VALANX’s shift from technology development to therapeutic application of its GoldenSite platform. 30 October 2025
Pharmaceutical
Danish pharma major Novo Nordisk today confirmed that it submitted an unsolicited proposal to acquire Metsera, aiming to outbid US pharma giant Pfizer, which just last month announced its own offer to acquire Metsera. 30 October 2025
Biotechnology
Swiss drug developer Oculis Holding today announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares, 0.01 francs nominal value per share, at a price of $20.25 per share for total gross proceeds of $110 million before deducting underwriting discounts and commissions and offering expenses. 30 October 2025
Biotechnology
US biotech Dewpoint Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to DPTX3186, its first-in-class condensate modulator for the treatment of gastric cancer. 29 October 2025
Biotechnology
US clinical stage biotech Armata Pharmaceuticals’ investigational phage therapy, AP-SA02, demonstrated earlier resolution in patients with Staphylococcus aureus bacteremia (SAB) in a Phase IIa trial, reinforcing the growing clinical promise of bacteriophage-based treatments. 29 October 2025
Biotechnology
US biotech Zag Bio announced the company’s launch with $80 million in financing, including a recently closed Series A financing. 29 October 2025
Biotechnology
Australian biotech Myrio Therapeutics has joined forces with the University of Pennsylvania’s Perelman School of Medicine and NYU Langone Health to accelerate the development of next-generation immunotherapies for solid tumors. 29 October 2025
Pharmaceutical
China-headquartered Innovent Bio has announced that the fourth Phase III trial DREAMS-3 of mazdutide, a glucagon-like peptide-1 (GLP-1) and glucagon (GCG) dual receptor agonist, has met its primary endpoint. 28 October 2025
Pharmaceutical
US biopharma newcomer Organon has endured a tough time in the stock market and faces having to repair its reputation following a damaging drama involving its now departed chief executive. 28 October 2025
Biotechnology
USA-based Intellia Therapeutics has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase III trials of nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), respectively. 28 October 2025
Biotechnology
USA-based CNS specialist MapLight Therapeutics successfully made its public debut on Sunday evening, raising more than $250 million as it advances its ML-007C-MA formulation that could set it apart from other muscarinic agonists by improving efficacy while still avoiding the side effects seen with dopaminergic atypical antipsychotics. 28 October 2025
Biotechnology
UK pharma major GSK and private French biotech Syndivia company, which is focused on next-generation antibody-drug conjugate (ADCs), today announced an agreement granting GSK exclusive worldwide rights to develop and commercialize a pre-clinical ADC for metastatic castration-resistant prostate cancer (mCRPC). 28 October 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A TechBio company that specializes in developing personalized vaccines and immunotherapies through its advanced AI-Immunology™ platform. The company bridges artificial intelligence technology, bioinformatics, and drug development to bring novel immunotherapies to patients facing cancer and infectious diseases.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze